Response to Comments: MolDX: Breast Cancer Index® (BCI) Gene Expression Test

This document is a response-to-comments notice for the MolDX: Breast Cancer Index (BCI) Gene Expression Test Local Coverage Determination (LCD DL37822). It reports the comment period (05/28/2020–07/12/2020), the LCD notice start date (03/25/2021), and the effective date (05/10/2021). The policy text provided contains no clinical coverage criteria, limitations, documentation requirements, or frequency limits.